Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells.

Science translational medicine - 18 Jul 2018

Kauko Otto, O'Connor Caitlin M, Kulesskiy Evgeny, Sangodkar Jaya, Aakula Anna, Izadmehr Sudeh, Yetukuri Laxman, Yadav Bhagwan, Padzik Artur, Laajala Teemu Daniel, Haapaniemi Pekka, Momeny Majid, Varila Taru, Ohlmeyer Michael, Aittokallio Tero, Wennerberg Krister, Narla Goutham, Westermarck Jukka

Abstract excerpt

Kinase inhibitor resistance constitutes a major unresolved clinical challenge in cancer. Furthermore, the role of serine/threonine phosphatase deregulation as a potential cause for resistance to kinase inhibitors has not been thoroughly addressed. We characterize protein phosphatase 2A (PP2A) activity as a global determinant of KRAS-mutant lung cancer cell resistance across a library of >200 kinase inhibitors....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cellular Senescence
Share to MAP Kinase Signaling System

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, Nude

Share to Mitogen-Activated Protein Kinase Kinases

Share to Protein Phosphatase 2

Share to Proto-Oncogene Proteins c-akt

Share to Proto-Oncogene Proteins p21(ras)

Share to TOR Serine-Threonine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 30021885
DOI: 10.1126/scitranslmed.aaq1093
PMCID: PMC8335581

Genes

KRAS
MYC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells.PMID 30021885Read ↗

A PP2A molecular glue overcomes RAS/MAPK inhibitor resistance in KRAS-mutant non-small cell lung cancer.Semantic proximity Read ↗

Rules for PP2A-controlled phosphosignalling and drug responsesSemantic proximity Read ↗

Overcoming Adaptive Resistance to KRAS and MEK Inhibitors by Co-targeting mTORC1/2 Complexes in Pancreatic Cancer.Semantic proximity Read ↗

High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886).Semantic proximity Read ↗

Acquired resistance to the PRMT5 inhibitor confers collateral sensitivity to MEK inhibition in MTAP-null non-small cell lung cancerSemantic proximity Read ↗

Developing SHP2-based combination therapy for KRAS-amplified cancer.Semantic proximity Read ↗

Phosphatome profiling reveals PTPN2, PTPRJ and PTEN as potent negative regulators of PKB/Akt activation in Ras-mutated cancer cells.Semantic proximity Read ↗

Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors.Semantic proximity Read ↗

PTEN deficiency facilitates gemcitabine efficacy in cancer by modulating the phosphorylation of PP2Ac and DCKSemantic proximity Read ↗

Global Phosphoproteomics Reveal CDK Suppression as a Vulnerability to KRas Addiction in Pancreatic CancerSemantic proximity Read ↗

SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AMLSemantic proximity Read ↗

JC-010a, a novel selective SHP2 allosteric inhibitor, overcomes RTK/non-RTK-mediated drug resistance in multiple oncogene-addicted cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.